Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSLLY CSL	$79.75 +0.7%	$77.98	$70.22 ▼ $109.00	$77.23B	0.79	95,205 shs	33,946 shs
GSK GSK	$38.70 -0.6%	$37.27	$31.72 ▼ $45.01	$79.84B	0.51	4.84 million shs	3.67 million shs
MKGAF Merck KGaA	$132.58 +1.6%	$135.43	$118.05 ▼ $200.56	$17.13B	0.96	701 shs	469 shs
ZTS Zoetis	$162.92 +0.6%	$156.48	$139.70 ▼ $200.33	$72.11B	0.94	2.53 million shs	2.73 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSLLY CSL	0.00%	+2.76%	+2.64%	-2.55%	-12.97%
GSK GSK	0.00%	+2.82%	+3.21%	+5.65%	-15.46%
MKGAF Merck KGaA	0.00%	+1.82%	-0.47%	-4.76%	-27.27%
ZTS Zoetis	0.00%	-0.07%	+6.82%	+1.57%	-5.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CSLLY CSL	1.4194 of 5 stars	0.0	5.0	1.7	0.0	1.3	0.0	1.3
GSK GSK	1.9411 of 5 stars	1.2	3.0	2.5	0.0	2.9	0.0	2.5
MKGAF Merck KGaA	0.9667 of 5 stars	0.0	1.0	0.0	0.0	1.6	0.0	3.1
ZTS Zoetis	4.6046 of 5 stars	3.6	3.0	4.2	0.4	4.1	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CSLLY CSL	4.00	Strong Buy	N/A	N/A
GSK GSK	2.42	Hold	$40.58	4.88% Upside
MKGAF Merck KGaA	4.00	Strong Buy	N/A	N/A
ZTS Zoetis	3.10	Buy	$212.75	30.59% Upside

Current Analyst Ratings Breakdown

Latest MKGAF, GSK, CSLLY, and ZTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00
4/28/2025	GSK GSK	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/15/2025	GSK GSK	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$35.25
4/14/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$180.00 ➝ $165.00
2/27/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$200.00 ➝ $205.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CSLLY CSL	$14.80B	5.22	$3.83 per share	20.80	$20.07 per share	3.97
GSK GSK	$31.53B	2.53	$6.12 per share	6.32	$8.07 per share	4.79
MKGAF Merck KGaA	$22.72B	0.75	$39.93 per share	3.32	$212.00 per share	0.63
ZTS Zoetis	$9.29B	7.81	$7.32 per share	22.26	$10.65 per share	15.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CSLLY CSL	$2.64B	N/A	0.00	19.50	1.59	N/A	N/A	N/A	N/A
GSK GSK	$3.29B	$1.94	24.34	8.32	1.12	8.13%	48.59%	11.11%	7/30/2025 (Estimated)
MKGAF Merck KGaA	$3.06B	$6.81	20.24	12.57	N/A	12.60%	10.17%	5.74%	8/7/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	29.78	24.14	2.78	26.86%	53.82%	18.86%	8/5/2025 (Estimated)

Latest MKGAF, GSK, CSLLY, and ZTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CSLLY CSL	$1.20	1.50%	N/A	N/A	N/A
GSK GSK	$1.68	4.34%	-17.33%	86.60%	N/A
MKGAF Merck KGaA	N/A	N/A	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.23%	+18.66%	35.91%	14 Years

Latest MKGAF, GSK, CSLLY, and ZTS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CSLLY CSL	0.58	2.18	0.97
GSK GSK	1.12	0.78	0.52
MKGAF Merck KGaA	0.27	1.31	0.84
ZTS Zoetis	1.09	1.75	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CSLLY CSL	0.03%
GSK GSK	15.74%
MKGAF Merck KGaA	0.10%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CSLLY CSL	N/A
GSK GSK	10.00%
MKGAF Merck KGaA	N/A
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CSLLY CSL	30,000	968.42 million	N/A	Not Optionable
GSK GSK	90,100	2.06 billion	1.87 billion	Optionable
MKGAF Merck KGaA	62,908	129.24 million	N/A	Not Optionable
ZTS Zoetis	13,800	445.21 million	447.08 million	Optionable

MKGAF, GSK, CSLLY, and ZTS Headlines

Recent News About These Companies

Connecticut Wealth Management LLC Decreases Stock Position in Zoetis Inc. (NYSE:ZTS)

May 24 at 7:31 AM | marketbeat.com

Novem Group Acquires New Holdings in Zoetis Inc. (NYSE:ZTS)

May 24 at 6:06 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

May 24 at 5:57 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Bought by Two Sigma Investments LP

May 24 at 4:46 AM | marketbeat.com

Tidal Investments LLC Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

May 24 at 4:45 AM | marketbeat.com

State of Wyoming Acquires 1,944 Shares of Zoetis Inc. (NYSE:ZTS)

May 24 at 4:36 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

May 23 at 6:43 AM | marketbeat.com

USS Investment Management Ltd Sells 10,698 Shares of Zoetis Inc. (NYSE:ZTS)

May 23 at 6:42 AM | marketbeat.com

334,197 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Voloridge Investment Management LLC

May 23 at 6:27 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Zurich Insurance Group Ltd FI

May 23 at 6:07 AM | marketbeat.com

Zoetis (NYSE:ZTS) Declares US$0.50 Dividend Per Share For Q3 2025

May 23 at 12:05 AM | finance.yahoo.com

Dr. Mark Stetter Elected to Zoetis Board of Directors

May 22 at 4:15 PM | businesswire.com

Williams Jones Wealth Management LLC. Has $156.23 Million Position in Zoetis Inc. (NYSE:ZTS)

May 22 at 6:18 AM | marketbeat.com

4,490 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by iSAM Funds UK Ltd

May 22 at 6:00 AM | marketbeat.com

Vident Advisory LLC Purchases 1,564 Shares of Zoetis Inc. (NYSE:ZTS)

May 22 at 6:00 AM | marketbeat.com

Westwood Holdings Group Inc. Buys 1,527 Shares of Zoetis Inc. (NYSE:ZTS)

May 22 at 5:35 AM | marketbeat.com

Silvercrest Asset Management Group LLC Decreases Stake in Zoetis Inc. (NYSE:ZTS)

May 22 at 4:57 AM | marketbeat.com

Zoetis Declares Third Quarter 2025 Dividend

May 22 at 2:47 AM | finance.yahoo.com

Jim Cramer on Zoetis (ZTS): “It Does Seem to Be Dead Money”

May 22 at 2:47 AM | msn.com

Analysts Set Zoetis Inc. (NYSE:ZTS) PT at $212.75

May 22 at 2:39 AM | americanbankingnews.com

Zoetis Announces Q3 2025 Dividend of $0.50

May 21, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MKGAF, GSK, CSLLY, and ZTS Company Descriptions

CSL OTCMKTS:CSLLY

$79.75 +0.59 (+0.75%)

As of 05/23/2025 03:59 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

GSK NYSE:GSK

$38.70 -0.23 (-0.58%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$39.12 +0.42 (+1.10%)

As of 05/23/2025 07:48 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Merck KGaA OTCMKTS:MKGAF

$132.58 +2.08 (+1.59%)

As of 05/23/2025 03:34 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Zoetis NYSE:ZTS

$162.92 +0.95 (+0.59%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$162.29 -0.63 (-0.39%)

As of 05/23/2025 07:57 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time